Sulbactam-durlobactam: Difference between revisions
From IDWiki
Content deleted Content added
Created page with "== Background == * β-lactam-β-lactamase inhibitor antibiotic * Half-life 2.15 and 2.52 hours, respectively == Dosing == * Hospital-acquired pneumonia/ventilator-associated pneumonia caused by Acinetobacter baumannii complex: 2 g IV over 3 hours q6h for 7 to 14 days === Renal Dosing === {| class="wikitable" !CrCl !Dose |- |≥130 |2 g q4h |- |45-129 |normal dose, 2 g q6h |- |30-44 |2 g q8h |- |15-29 |2 g q12h |- |<15 |2 g q12h x3 doses followed by q24h |..." |
No edit summary |
||
| Line 34: | Line 34: | ||
|Based on EFR |
|Based on EFR |
||
|} |
|} |
||
== Safety == |
|||
=== Adverse Effects === |
|||
* Routine for antibiotics: [[Hypersensitivity reaction|hypersensitivity]] and [[Clostridioides difficile]] |
|||
* Elevated liver enzyes |
|||
* Diarrhea |
|||
* Anemia |
|||
* Hypokalemia |
|||
[[Category:Β-lactams]] |
[[Category:Β-lactams]] |
||
Latest revision as of 15:18, 17 March 2026
Background
- β-lactam-β-lactamase inhibitor antibiotic
- Half-life 2.15 and 2.52 hours, respectively
Dosing
- Hospital-acquired pneumonia/ventilator-associated pneumonia caused by Acinetobacter baumannii complex: 2 g IV over 3 hours q6h for 7 to 14 days
Renal Dosing
| CrCl | Dose |
|---|---|
| ≥130 | 2 g q4h |
| 45-129 | normal dose, 2 g q6h |
| 30-44 | 2 g q8h |
| 15-29 | 2 g q12h |
| <15 | 2 g q12h x3 doses followed by q24h |
| IHD | 2 g q12h x3 doses followed by q24h |
| CRRT | Based on EFR |
Safety
Adverse Effects
- Routine for antibiotics: hypersensitivity and Clostridioides difficile
- Elevated liver enzyes
- Diarrhea
- Anemia
- Hypokalemia
